Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNC109 in Recurrent Glioblastoma
NCT06616727Phase 1Enrolling by invitation
- Sponsor
- Simnova Biotherapeutics
- Start
- Dec 2023
- Primary completion
- Dec 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SNC-109 in glioblastoma (GBM), sponsored by Simnova Biotherapeutics. Primary endpoints: Incidence of treatment related adverse events at 28 days and Dose Limitation Toxicity at 28 days. Started Dec 2023; status: enrolling by invitation.
02
Drugs
SNC-109
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT06616727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06616727.